The identification of specific biological and molecular markers is essential for accurate diagnosis, prognostic assessment, and treatment planning. Elevated levels of β2-M, LDH, CA 125, TNF-α, IL-2, and sCD44 are all associated with increased tumor burden and poor prognosis in NHL. Here, TNF is linked to non-Hodgkin lymphoma.